INTRODUCTION {#s1}
============

Donor-derived hematologic malignancies are rare complications of hematopoietic cell transplantation (HCT) with an incidence of ∼0.1% ([@MCS002980SCHC11]). However, donor-derived neoplasms may range as high as 5% given the potential for underestimation due to the historic limitation of unequivocally demonstrating donor origin ([@MCS002980SCHC27]). The first published report of a donor-derived hematologic malignancy was in 1971 ([@MCS002980SCHC6]), and following this first case, several case reports, series, and retrospective surveys have documented less than 150 cases ([@MCS002980SCHC24]; [@MCS002980SCHC11]). Infections and other diseases, such as autoimmune disorders ([@MCS002980SCHC15]) or hematologic malignancy, have been shown to be transmitted from the donor, and in some cases these diseases have been proven to be present at the time of transplantation ([@MCS002980SCHC2]), whereas in others the donors remain well without evidence of disease ([@MCS002980SCHC27]; [@MCS002980SCHC4]). Several mechanisms for the development of donor-derived malignancy have been proposed and comprehensively reviewed ([@MCS002980SCHC27]), but a consolidated hypothesis remains elusive given the heterogeneity of the cases reported to date. This heterogeneity is evident in two recent studies of donor-derived hematological malignancies. In one study, a *TET2* mutation was identified as the founding lesion of a recipient\'s donor-derived myelodysplastic syndrome (MDS) that originated from the donor\'s clonal hematopoiesis of indeterminate potential (CHIP) ([@MCS002980SCHC21]). In a second study, a donor-derived AML with a *NPM1* mutation was only present in the recipient, whereas the donor reportedly remains without mutation and clinically well ([@MCS002980SCHC20]).

Here we describe, with comprehensive next-generation sequencing, the clonal dynamics of a donor-derived MDS in a young adult with monosomy 7 and a loss of function *ASXL1* mutation.

Clinical Presentation and Course {#s1a}
--------------------------------

A 15-yr-old male presented for medical attention because of chronic headaches; his laboratory workup revealed leukocytosis (WBC: 130,000/mm^3^) and thrombocytopenia (platelets: 113,000/mm^3^). Diagnostic bone marrow studies revealed 90% blasts by morphology with an immunophenotype consistent with B-lymphoblastic leukemia (B-ALL). Conventional karyotyping showed an abnormal karyotype---46,XY, t(2;9)(q21;q34) \[14\]; 46,XY \[6\]---and fluorescence in situ hybridization (FISH) studies demonstrated an *ABL1* fusion. The patient started induction therapy with a seven-drug regimen on a Total Therapy for Leukemia protocol ([@MCS002980SCHC18]). Following induction and consolidation therapy, the patient\'s minimal residual disease (MRD) remained positive; therefore, he received reintensification therapy in preparation for HCT. The patient\'s MRD remained positive at a low level until after HCT ([Fig. 1](#MCS002980SCHF1){ref-type="fig"}A). He received a matched (7/8) unrelated donor transplant from a 43-yr-old female donor. His pretransplant conditioning regimen included myeloablative total body irradiation, cyclophosphamide, thiotepa, and antithymocyte globulin (ATG). Following transplant, the patient had many transplant-related morbidities including acute, and later chronic, graft versus host disease of the skin, gut, and liver, chronic lung disease, and chronic renal failure due to BK virus nephropathy requiring intermittent dialysis. Forty-four months after his initial leukemia diagnosis, an incidentally found left renal mass was confirmed to be renal cell carcinoma (RCC) positive for a Xp11.2 lesion with a *ASPSCR1*-*TFE3* fusion transcript; he was treated with a left nephrectomy. Eleven months following the left RCC diagnosis, the patient was diagnosed with a right RCC with the Xp11.2 alteration but no *ASPSCR1-TFE3* fusion. Therefore, the right RCC was determined to represent a second primary tumor also treated with a nephrectomy, leaving the patient anephric and dialysis-dependent. Five months following the second RCC, the patient developed a lower lip lesion that was diagnosed as squamous cell carcinoma (SCC) and surgically excised. At 5.5 yr following the patient\'s initial B-ALL diagnosis (4 yr post-HCT), the patient was diagnosed with MDS following a routine annual bone marrow evaluation demonstrating multilineage dysplasia and an abnormal karyotype, including monosomy 7 ([Fig. 1](#MCS002980SCHF1){ref-type="fig"}B,C). Molecular analyses of the patient\'s marrow samples showed 100% chimerism, which was further supported by FISH for Chromosome X, suggesting that the MDS is donor-derived (dMDS). Subsequently, his peripheral counts were monitored frequently as he became transfusion-dependent. Intermittent bone marrow evaluations never showed progression to AML. One year following the MDS diagnosis, the patient developed another lip lesion (upper lip) that was confirmed to be SCC with significant local invasion. No additional therapy was pursued. Three months later imaging confirmed the development of several metastatic pulmonary nodules, and he succumbed to his diseases one month later following an episode of pneumonia.

![Clinical and response characteristics of dMDS. (*A*) MRD, as measured by flow cytometric analysis of the leukemia-associated immunophenotype or chimerism (VNTR PCR analysis), levels at listed time after initial B-ALL diagnosis. (*B*) Morphologic evaluation of the bone marrow biopsy and aspirate at the time of dMDS diagnosis showing hypocellularity and dysplastic changes. (*C*) Conventional karyotype (*left* panel) of the MDS sample demonstrating partial deletion of Chromosomes 6 and monosomy 7 and XY FISH (*right* panel) showing only X chromosomes (red probe) and the absence of Y, consistent with donor origin.](MCS002980Sch_F1){#MCS002980SCHF1}

Genomic Analysis {#s1b}
----------------

Twelve distinct samples were available for genomic interrogation from this patient as part of an institutional IRB-approved protocol for the collection and genomic analysis of patient samples following informed consent. These samples provide an opportunity to comprehensively follow the clonal dynamics of this patient\'s presumed donor-derived MDS. This includes three pretransplant samples, including his original diagnostic B-ALL, as well as nine posttransplant samples ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)). Although material directly from his allograft was not available, we did have access to a sample collected from his bone marrow 22 d after the allograft, at which time clinical testing showed 99% donor engraftment. In addition, purified lymphocytes were obtained by flow cytometry as a source of "germline" genomic DNA, and bone marrow fibroblasts/stromal cells were cultured to provide an additional source of the patient\'s germline. Whole-exome sequencing (Illumina Nextera Rapid Capture Expanded Exome, 62 Mb) and whole-genome sequencing (WGS) were performed on the MDS sample ([Supplemental Tables 2--4](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)). The diagnostic ALL was characterized by WGS. Using this information, we also established a targeted panel (Haloplex, Agilent Technologies) to follow five variants in the B-ALL and 28 in the MDS as well as 11 single-nucleotide polymorphisms (SNPs) to distinguish the donor and patient/recipient ([Fig. 2](#MCS002980SCHF2){ref-type="fig"}A,B; [Supplemental Tables 5--9](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)).

![Clonal dynamics of dMDS. (*A*) Minor allele frequencies (MAF) of SNPs unique to patient (ALL1 & ALL2) and donor (MDS1 & MDS2) at various time points. Patient-specific SNPs are only present prior to transplant and donor-specific SNP only after transplant. (*B*) Chart demonstrating the sequencing approach used for each sample at each time point. (*C*) Copy number analysis from WES data for the dMDS sample showing monosomies of Chromosomes 6 and 7. The chromosomes are arranged *left* to *right* (Chr1 on the far *left*), and odd chromosomes are highlighted in green and even chromosomes in black. (*D*) VAF timeline of pathologic mutations identified in the dMDS via targeted sequencing (HaloPlex). The Day 2071 sample was a sorted myeloid population versus a bulk marrow population as in the other time points; therefore, the values shown are corrected by a factor of 2 given that the lymphocyte population comprised 50% of that initial bulk population. (*E*) VAF timeline of *ASXL1* Y700\* mutation identified in the dMDS via allele-specific droplet digital PCR. Absolute read counts for the mutant allele (numerator) and total reads (denominator) are listed. Notes for *D*,*E*: The *ASXL1* mutation is denoted by the blue triangle. The vertical gray hatched lines demarcate the time when morphologic evidence of MDS is present. The orange lines demonstrate the median VAF for the time point.](MCS002980Sch_F2){#MCS002980SCHF2}

First, we unequivocally demonstrate that the MDS is derived from the donor by tracking SNPs that distinguish the donor and recipient cells ([Fig. 2](#MCS002980SCHF2){ref-type="fig"}A). These data clearly show that the genotype of the MDS is consistent with donor cells. In addition, our sequencing of the B-ALL and dMDS samples show neoplasms with dramatically different mutational profiles. The B-ALL sample has a complex rearrangement of Chromosomes 2, 9, and 15 that involves *ABL1*, consistent with a Ph-like ALL, as well as a *CREBBP* splice site mutation involving exon 21. These alterations were not present in the MDS. In contrast, the MDS sample from day 2071 has 47 somatic alterations (32 missense, 1 nonsense, 11 silent, and 3 splice region mutations), including a nonsense mutation in *ASXL1* (c.T2100A; p.Y700\*) at a variant allele frequency (VAF) of 0.46 (WES) ([Table 1](#MCS002980SCHTB1){ref-type="table"}). Although *ASXL1* mutations are common in adult MDS ([@MCS002980SCHC9]), they are less common in pediatric MDS ([@MCS002980SCHC17]; [@MCS002980SCHC22]). We also confirmed the monosomy 7, as well as a focal deletion of Chromosome 6 ([Fig. 2](#MCS002980SCHF2){ref-type="fig"}C). We then sequenced all 12 samples using the targeted panel (average median coverage 534×) to determine when the *ASXL1* variant and 27 other somatic mutations identified in the MDS sample were present relative to the transplant and the diagnosis of MDS. The median VAF for the 28 dMDS variants first rose above 2% at day 1657, which is 1470 d after the bone marrow transplant and 358 d prior to any morphologic evidence of dysplasia ([Fig. 2](#MCS002980SCHF2){ref-type="fig"}D). Specifically, the *ASXL1* variant was first detected at a VAF \>2% at day 1657, although supporting reads were first present at day 1000. We used allele-specific droplet digital PCR to confirm the presence of *ASXL1* mutant alleles as early as Day 1000. Moreover, we show that this variant is not detectable until day 1000 (813 d after HCT) with a steady increase after that time ([Fig. 2](#MCS002980SCHF2){ref-type="fig"}E; [Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)). In contrast, although we could detect low levels of the *CREBBP* mutation in the patient\'s B-ALL at day 66 ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)), this mutation was not present at any later time point, including the post-transplant MDS samples. Despite the presence of multiple cancers in the recipient, WGS analysis did not identify any obvious disease-causing germline variants in genes commonly implicated in cancer predisposition syndromes ([Supplemental Tables 10, 11](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1)), nor were any germline variants in MDS/AML genes present in the donor. In silico predictions scored a novel *TOP2B* variant as the most deleterious (CADD score: 35) variant in the patient\'s germline (<http://cadd.gs.washington.edu/info>)([@MCS002980SCHC12]). Although *TOP2B* alterations have been implicated in both de novo and therapy-related AML ([@MCS002980SCHC14]; [@MCS002980SCHC25]), the significance of this variant in this context is uncertain.

###### 

Significant sequence variant identified in donor-derived myelodysplastic syndrome

  Gene      Chr: position GRCh37 (hg19)   HGVS DNA reference   HGVS protein reference   Variant type            Predicted effect   Genotype
  --------- ----------------------------- -------------------- ------------------------ ----------------------- ------------------ ----------------------
  *ASXL1*   Chr 20: 31022615              c.2100T\>A           p\. Tyr700Stop           Nonsense substitution   Loss of function   Somatic heterozygous

DISCUSSION {#s2}
==========

The development of a myeloid neoplasm arising from cells of donor origin following HCT could result from unknowingly transferring cells that harbor germline mutations or cells that have acquired mutations associated with clonal hematopoiesis (e.g., *TET2* \[[@MCS002980SCHC21]\] or *DNMT3A* \[[@MCS002980SCHC28]\]). *ASXL1* variants are commonly observed in patients with CHIP ([@MCS002980SCHC10]). Considering the high VAF of the *ASXL1* variant observed for this donor-derived MDS, the most likely explanation in this case is that a rare hematopoietic stem and progenitor cell (HSPC) with the *ASXL1* p.Y700\* mutation was unknowingly transferred to the recipient during HCT. However, our digital droplet PCR data show that the variant was not detectable until 813 d after the HCT, suggesting that this mutation potentially arose after the HCT. Further, CHIP is uncommon in individuals in their 40s ([@MCS002980SCHC10]; [@MCS002980SCHC1]). However, even the most sensitive sequencing techniques cannot completely rule out that a preexisting mutation in a rare HSPC was transferred from the donor. Alternatively, the donor-derived MDS in this case could have resulted in the recipient as a result of cell extrinsic pressures, such as microenvironmental stresses ([@MCS002980SCHC7]; [@MCS002980SCHC5]; [@MCS002980SCHC19]), including damaging stromal mutations, residual effects of cytotoxic chemotherapy, radiation bystander effects, or impaired immune surveillance ([@MCS002980SCHC27]). Although no definitive germline variants linked to cancer predisposition were identified in this patient by WGS, the presence of multiple malignancies does suggest a potential permissive environment. Likewise, dMDS has been reported in a recipient with Fanconi anemia ([@MCS002980SCHC8]). To our knowledge, the donor remains healthy without clinical symptoms (e.g., peripheral cytopenias). Like previously reported cases, this patient developed monosomy 7 and received hematopoietic growth factors (in our case erythropoietin) prior to developing dMDS, though none of the previously reported cases had ALL as the initial diagnosis ([@MCS002980SCHC3]). In addition to providing critical insights into the clonal progression of donor-derived MDS, our data also demonstrate the utility of sequencing approaches in the diagnosis of myeloid neoplasms after HCT, as we detected MDS-related mutations nearly 3 yr prior to a morphologic diagnosis.

METHODS {#s3}
=======

MRD was measured by flow cytometry and defined as negative when the leukemia-associated immunophenotype was expressed on \<0.01% of bone marrow mononucleated cells. Post-HCT chimerism was measured via variable number of tandem repeats (VNTR) PCR analysis. Whole-genome, whole-exome, and targeted amplicon sequencing and analyses were completed on samples paired with flow-sorted lymphocytes (as a source of germline genomic DNA) as previously described ([@MCS002980SCHC22],[@MCS002980SCHC23]). Patient fibroblasts were cultured from the banked dMDS sample (Day 2239). Analysis of WGS and WES data, which include mapping, coverage, and quality assessment, SNV/indel detection, tier annotation for sequence mutations, prediction of deleterious effects of missense mutations, and identification of loss of heterozygosity, were described previously ([@MCS002980SCHC29]). The detection and annotation of germline variants were performed by a workflow named "medal ceremony" described previously ([@MCS002980SCHC30]). Coverage data and statistics are documented in [Supplemental Table 12](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002980/-/DC1). The mean coverage for WES and WGS was 86× and 52×, respectively. Pair-end reads of an average length of 100 and 151 were obtained for WES and WGS, respectively. Single-nucleotide variations (SNVs) were classified into the following four tiers: tier 1, coding synonymous, nonsynonymous, splice site, and noncoding RNA variants; tier 2, conserved variants (cutoff: conservation score greater than or equal to 500 based on either the phastConsElements28way table or the phastConsElements17way table from the UCSC genome browser) and variants in regulatory regions annotated by UCSC annotation (regulatory annotations included are targetScanS, ORegAnno, tfbsConsSites, vistaEnhancers,eponine, firstEF, L1 TAF1 Valid, Poly(A), switchDbTss, encodeUViennaRnaz, laminB1, cpgIslandExt); tier 3, variants in nonrepeat masked regions; and tier 4, the remaining variants. Structural variations in WGS were analyzed using CREST ([@MCS002980SCHC26]). For copy-number analysis, SAMtools ([@MCS002980SCHC13]) mpileup command was used to generate an mpileup file from matched normal and tumor BAM files with duplicates removed. VarScan2 was then used to take the mpileup file to call somatic CNAs after adjusting for normal/tumor sample read coverage depth and GC content. Circular Binary Segmentation algorithm ([@MCS002980SCHC16]) implemented in the DNAcopy R package was used to identify the candidate CNAs for each sample. B-allele frequency info for all high-quality dbSNPs heterozygous in the germline sample was also used to assess allele imbalance. For Haloplex analysis, samples were aligned and SNVs were called using Agilent SureCall software (*Agilent HaloPlex Target Enrichment: Design and Analysis of Clinical Research Panels,* Publication number 5991-1919EN). The software merges duplicate sequencing reads into single reads using a molecular barcode system, and the number of merged reads is recorded in the resulting bam file. Using these numbers, absolute read count coverage for every SNV was calculated. In some instances, reads collapsed from a single barcode (reads that were not duplicated) were excluded from the analysis. All read counts were performed using the pysam module (<https://github.com/pysam-developers/pysam>) of the Python computing language (<http://www.python.org/>). The average median read depth for the 12 samples analyzed by targeted sequencing (Haloplex) was 534×. Allele-specific droplet digital PCR was performed on 25 ng of template gDNA using TaqMan Genotyping Master Mix (Applied Biosystems) and custom *ASXL1* TaqMan (Thermo-Fisher) primers and probes \[5′-TCTACAGCGAACACAACTACTGC (forward), 5′-TCCGGCCTGGGTATGCT (reverse), 5′-VIC-CATTTAGAGGATAAGGCG (wild-type), 5′-FAM-CCATTTAGAGGTTAAGGCG (mutant)\]. Droplets were generated using the RainDance Source instrument and amplification was performed with the following conditions: 10 min at 95°C, 40 cycles of 95°C for 30 sec, 60°C for 1 min. Fluorescence of the amplified droplets was detected by the RainDance Sense instrument and the resulting data was analyzed using RainDrop Analyst II software.

ADDITIONAL INFORMATION {#s4}
======================

Data Deposition and Access {#s4a}
--------------------------

DNA sequencing data are deposited to the European Genome-phenome Archive (EGA; [www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) under accession EGAS00001002202. The *ASXL1* p.Y700\* variant was submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000778455.
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